Noxcovid trial advances to final stage
Drug development company Noxopharm has reported positive results for use in its drug Veyonda in preventing septic shock in seriously ill patients infected by the Covid-19 virus. The Sydney company tested 26 patients with varying doses of Veyonda, a product based on an existing anti-cancer drug. The patients with moderately severe disease had very poor…